Generic Medicine Info
May be taken with or without food. Side effects eg sleepiness/drowsiness may be reduced if taken immediately after meals.
Severe respiratory insufficiency, myasthenia gravis, sleep apnoea syndrome. Acute narrow-angle glaucoma. Severe hepatic impairment. Lactation. Concomitant use with strong CYP3A inhibitors, except ritonavir.
Special Precautions
Patient with depression or suicidal ideation, respiratory disease, history of alcohol or drug abuse. Debilitated patients or those with concomitant illness. Patients taking opioids or ritonavir. Avoid abrupt withdrawal. Renal and mild to moderate hepatic impairment. Elderly. Pregnancy. Patient Counselling This drug may impair cognitive and motor functions, if affected, do not drive or operate machinery. Monitoring Parameters Monitor respiratory and CV status. Assess patients for risk of abuse, misuse, and addiction. Monitor for signs and symptoms of respiratory depression and sedation.
Adverse Reactions
Significant: Anterograde amnesia, restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate behaviour, physical and emotional dependence. Eye disorders: Blurred vision. Gastrointestinal disorders: Dry mouth, constipation, nausea, increased salivation. General disorders and administration site conditions: Fatigue, lethargy. Investigations: Increased or decreased weight. Metabolism and nutrition disorders: Decreased appetite. Nervous system disorders: Sedation, somnolence, ataxia, memory impairment, dysarthria, dizziness, headache, balance disorder, abnormal coordination, tremors. Psychiatric disorders: Depression, confusional state, disorientation, anxiety, insomnia, hypersomnia, nervousness, disturbance in attention. Reproductive system and breast disorders: Increased or decreased libido, sexual dysfunction. Skin and subcutaneous tissue disorders: Dermatitis. Vascular disorders: Hypotension.
Drug Interactions
Additive CNS depressant effects with other psychotropic drugs, anticonvulsants, anaesthetics, antihistamines and other drugs that produce CNS depression. Increased plasma concentrations with nefazodone, fluvoxamine, fluoxetine, oral contraceptives, diltiazem, macrolide antibiotics (e.g. erythromycin, clarithromycin), and cimetidine. Decreased plasma concentrations with CYP3A4 inducers (e.g. carbamazepine, phenytoin). May increase the concentration of digoxin.
CIMS Class
ATC Classification
N05BA12 - alprazolam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on alprazolam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in